01 Commercial-Scale Fermentation Is Reshaping Ingredient Production Food biotechnology is moving from small research batches toward commercial-scale fermentation. Larger facilities improve supply reliability and allow food brands to test these ingredients in retail products instead of limited pilots. This change also increases demand for strain design, bioreactors, purification systems, and contract manufacturing. Competition is therefore shifting toward companies that can combine biological performance with dependable, cost-efficient production and application support. In September 2025, Clean Food Group acquired a one-million-litre fermentation facility in Knowsley, UK, gaining immediate capacity to manufacture yeast-derived oils and fats.
01 Efficient and Clean-Label Processing Accelerates Biosolution Adoption Food manufacturers are adopting enzymes and microbial cultures to improve yield, texture, shelf life, and production efficiency. These biosolutions can operate under controlled conditions and may reduce energy, water, or raw-material losses compared with conventional treatments. They also help manufacturers develop simpler formulations while maintaining product performance, an important requirement in dairy, baking, beverages, and plant-based foods. Because a biological solution can address a specific processing problem without major factory redesign, producers can introduce it across existing production lines.
01 Limited Consumer Familiarity Restricts Regular Product Purchases Limited consumer understanding can slow the adoption of foods made through newer biotechnology methods. Terms such as precision fermentation or engineered microorganisms may sound unfamiliar, even when the finished ingredient resembles a known protein or vitamin. This creates additional spending on labeling, education, testing, and brand communication. Retailers may also delay shelf placement when expected repeat purchases remain uncertain. Consequently, technically successful products can struggle to achieve sufficient sales volume, limiting production scale and weakening price competitiveness.
01 Low-Emission Food and Feed Systems Create New Revenue Paths Biotechnology creates a commercial opening for food and feed products with lower environmental footprints. Start-ups can use microbes, enzymes, and cell-based processes to develop alternative proteins, improve feed conversion, or reduce agricultural methane emissions. Buyers facing climate targets need solutions whose performance and emission benefits can be measured at industrial scale. Public innovation funding can also reduce early scale-up risks.
01 Incomplete Safety Data Complicates Novel Ingredient Assessments Proving the safety of novel biotechnology-derived ingredients remains technically demanding. Developers must characterize the production organism, genetic changes, finished molecule, possible impurities, and consistency between batches. Protein products may also require evidence concerning digestibility, allergenicity, and nutritional effects. Missing or inconsistent datasets can trigger additional studies, extend assessment timelines, and raise development costs before commercial launch. Smaller companies may find this burden especially difficult because analytical work requires specialized laboratories and regulatory expertise.
June 2026 The EVERY Company entered a strategic partnership with Grupo Palacios Alimentación to commercialize precision fermentation-derived egg proteins in European food products, expanding the adoption of biotechnology-enabled ingredients in the food industry.
May 2026 Formo secured a EUR 35 million venture debt financing to accelerate commercialization and scale-up of its precision fermentation-based dairy products, strengthening its food biotechnology manufacturing capabilities.
May 2026 Wildtype received U.S. FDA clearance for its cultivated coho salmon, becoming the first company authorized to commercialize cultivated seafood in the United States and marking a major regulatory milestone for food biotechnology.
February 2026 The Protein Brewery secured EUR 35 million in Series B funding to expand commercial production of its fermentation-derived protein ingredient Fermotein®, supporting large-scale food biotechnology applications.